Gilead’s Trodelvy Basks In TROPiCS With FDA Breast Cancer Nod

Company Lays Out Development Strategy In Q4 Earnings

Gilead announced the approval of Trodelvy for HR+/HER2- metastatic breast cancer • Source: Shutterstock

More from New Products

More from Scrip